Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.

The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.

Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month.

The post J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition appeared first on MedCity News.

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as peripheral neuropathic pain and bipolar disorder.

The post CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug appeared first on MedCity News.

Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation.

The post J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition appeared first on MedCity News.

The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products.

The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.

Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.

The post With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO appeared first on MedCity News.

Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.

The post FDA Calls for New Safety Warning for the Class of CAR T Cancer Therapies appeared first on MedCity News.

This year’s J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.

The post 7 JPM Announcements You Don’t Want to Miss appeared first on MedCity News.

Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.

The post J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition appeared first on MedCity News.

GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.

The post GSK Drug Pulled From Market Beats J&J Multiple Myeloma Med in Phase 3 Test appeared first on MedCity News.

Johnson & Johnson released research this month showing that its system for robotic-assisted bronchoscopy helped physicians achieve an over 15% improvement in overall diagnostic yield compared to traditional bronchoscopy. This could mean that fewer patients will have to “wait and see” while their cancer potentially gets worse.

The post J&J’s Robotic Bronchoscopy System Could Help Physicians Detect Cancer Sooner, Research Finds appeared first on MedCity News.

Oncology is already a big piece of Pfizer’s drug lineup. The portfolio is expanding to multiple myeloma with FDA approval of Elrexfio, a bispecific antibody that targets the cancer protein BCMA.

The post Pfizer Expands to Multiple Myeloma With FDA Approval for New Antibody Drug appeared first on MedCity News.

Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.

The post FDA Approves J&J Combo Drug for Prostate Cancers With Certain Genetic Signature appeared first on MedCity News.

Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.

The post J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug appeared first on MedCity News.

Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.

The post J&J Gets Foothold in Head & Neck Cancer With Deal for Nanobiotix’s Lead Program appeared first on MedCity News.

Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J&J exits the consumer business while Bausch + Lomb expands its product portfolio with its second deal in as many weeks.

The post Bausch + Lomb Continues Deal Streak With $106M Acquisition of J&J Eye Drops appeared first on MedCity News.

Johnson & Johnson’s oral psoriasis drug met the goals of a mid-stage clinical study, and the pharma giant now plans to advance the twice-daily pill to Phase 3 testing. J&J is one of several biopharmaceutical companies developing pill alternatives to biologic drugs that are injected or infused.

The post J&J Plans Phase 3 Trial to Keep Pace in the Chase for Oral Psoriasis Drugs appeared first on MedCity News.

Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.

The post J&J Expands in Cancer, Paying $245M for Two Next-Generation Cell Therapies appeared first on MedCity News.

Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.

The post J&J Portfolio Review Culls RSV Vaccine, Ending the Phase 3 Program appeared first on MedCity News.

A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.

The post J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test appeared first on MedCity News.

Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.

The post J&J Stops Work on HIV Vaccine After Failure in Phase 3 Clinical Trial appeared first on MedCity News.

Johnson & Johnson’s CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it’s crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.

The post J&J CEO: Our R&D Infrastructure Helps Us Maintain Innovation Amid an Uncertain Economy appeared first on MedCity News.

Johnson & Johnson is seeking FDA approval of a multiple myeloma drug that could become the first one addressing a novel target called GPRC5D. Data from the Phase 1/2 study supporting the biologics license application were presented in New Orleans during the annual meeting of the American Society of Hematology.

The post J&J Aims to Expand in Multiple Myeloma With First Drug for Novel Target appeared first on MedCity News.

FDA approval of Tecvayli, from Johnson & Johnson subsidiary Janssen Biotech, makes it the newest therapy that treats multiple myeloma by targeting the cancer protein BCMA. Though this off-the-shelf drug offers patients a more convenient dosing option, it comes with similar complication risks as other biologics approved for this type of blood cancer.

The post J&J multiple myeloma drug gets FDA nod, bringing patients an easier dosing option appeared first on MedCity News.

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.

The post ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more appeared first on MedCity News.

The FDA amended emergency authorization of Johnson & Johnson’s Covid-19 vaccine. In other regulatory news this past week, drug approvals include a cancer drug that converted its accelerated regulatory approval to a full regulatory nod, while several companies dealt with rejections or clinical trial setbacks.

The post Regulatory recap: J&J vaccine limits, full Enhertu approval, a Vertex hold & more appeared first on MedCity News.

The FDA approved Johnson and Johnson Vision Care’s Acuvue Theravision with the antihistamine Ketotifen to treat allergy-induced itchy eyes for contact lens wearers.

The post J&J receives FDA approval for drug-eluting contact lens appeared first on MedCity News.

Research of Johnson & Johnson’s baby powder included a prison study in which inmates, mostly Black men, were injected with asbestos. The study was intended to assess how asbestos’s effects on the skin compare to talc, the key component of baby powder.

The post Bloomberg: Court docs reveal J&J’s role in prison tests comparing talc to asbestos appeared first on MedCity News.

The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and Reata Pharmaceuticals.

The post FDA regulatory roundup: two approvals, three rejections & one clinical hold appeared first on MedCity News.